The company has been especially active in diabetes management with collaboration partners that include medical device giant Medtronic and DexCom.
Since the start of the year, Fitbit has made emphasized its interest in making disease management more than just a clinical study subject but part of its offer. To that end, it has been especially active in diabetes management with collaboration partners that include medical device giant Medtronic and DexCom. Fitbit CEO and chairman James Park outlined the company’s progress in a conference call late Wednesday to discuss the company’s earnings in the third quarter.
